Ayhan Kul1, Orhan Ateş2, Meltem Alkan Melikoğlu1, Mahir Uğur1, Nurinnisa Öztürk3, Gülsüm Erkayhan4, İbrahim Koçer2. 1. Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University Erzurum, Turkey. 2. Department of Ophtalmologia, Medical Faculty of Atatürk University Erzurum, Turkey. 3. Department of Biochemistry, Medical Faculty of Atatürk University Erzurum, Turkey. 4. Department of Ophtalmologia, Mersin Public Hospital, Mersin, Turkey.
Abstract
OBJECTIVES: This study aims to investigate the relationships between serum endocan, vascular endothelial growth factor (VEGF), and tumor necrosis factor-alpha (TNF-α) levels in active Behçet disease. PATIENTS AND METHODS: Forty patients with active Behçet disease (24 males, 16 females; mean age 37.6±8.7 years; range 20 to 50 years) and 40 healthy controls (22 males, 18 females; mean age 38.8±7.9 years; range 21 to 52 years) were included in this study. Both patient and control groups underwent a complete systemic and ophthalmic examination by the same specialist. Endocan, VEGF, and TNF-α levels were measured with an enzyme-linked immunosorbent assay kit in all subjects. RESULTS: Serum endocan levels were 775.2±479.3 ng/mL and 275.8±145.8 ng/mL in the patient and control groups, respectively. VEGF levels were 1768.2±900.5 pg/mL and 980.2±135.3 pg/mL in the patient and control groups, respectively. TNF-α levels were 22.4±74.3 pg/mL-1 and 11.4±16.9 pg/mL-1 in the patient and control groups, respectively. There was a statistically significant difference between groups in terms of serum endocan, VEGF, and TNF-α levels. There was a significant positive correlation between serum endocan and VEGF levels in the patient group (r=0.630; p<0.001). Also, there was a significant positive correlation between serum endocan and TNF-α levels in the patient group (r=0.713; p<0.001). CONCLUSION: Serum endocan level may be a new marker in evaluation of both the prognosis and activity of Behçet disease.
OBJECTIVES: This study aims to investigate the relationships between serum endocan, vascular endothelial growth factor (VEGF), and tumor necrosis factor-alpha (TNF-α) levels in active Behçet disease. PATIENTS AND METHODS: Forty patients with active Behçet disease (24 males, 16 females; mean age 37.6±8.7 years; range 20 to 50 years) and 40 healthy controls (22 males, 18 females; mean age 38.8±7.9 years; range 21 to 52 years) were included in this study. Both patient and control groups underwent a complete systemic and ophthalmic examination by the same specialist. Endocan, VEGF, and TNF-α levels were measured with an enzyme-linked immunosorbent assay kit in all subjects. RESULTS: Serum endocan levels were 775.2±479.3 ng/mL and 275.8±145.8 ng/mL in the patient and control groups, respectively. VEGF levels were 1768.2±900.5 pg/mL and 980.2±135.3 pg/mL in the patient and control groups, respectively. TNF-α levels were 22.4±74.3 pg/mL-1 and 11.4±16.9 pg/mL-1 in the patient and control groups, respectively. There was a statistically significant difference between groups in terms of serum endocan, VEGF, and TNF-α levels. There was a significant positive correlation between serum endocan and VEGF levels in the patient group (r=0.630; p<0.001). Also, there was a significant positive correlation between serum endocan and TNF-α levels in the patient group (r=0.713; p<0.001). CONCLUSION: Serum endocan level may be a new marker in evaluation of both the prognosis and activity of Behçet disease.
Authors: Filip Roudnicky; Cedric Poyet; Peter Wild; Sarah Krampitz; Fabrizia Negrini; Reto Huggenberger; Anja Rogler; Robert Stöhr; Arndt Hartmann; Maurizio Provenzano; Vivianne I Otto; Michael Detmar Journal: Cancer Res Date: 2012-12-14 Impact factor: 12.701
Authors: Emma Rennel; Sofie Mellberg; Anna Dimberg; Ludvig Petersson; Johan Botling; Adam Ameur; Jakub Orzechowski Westholm; Jan Komorowski; Philippe Lassalle; Michael J Cross; Pär Gerwins Journal: Exp Cell Res Date: 2007-02-06 Impact factor: 3.905
Authors: Eman Mostafa Nassef; Hemmat Ahmed Elabd; Basma Mohamed Mohamed Ali El Nagger; Hala Mohamed Elzomor; Hend Gamal Kotb; Seham Sabry; Boshra Ahmed Zaghloul; Asmaa S Hassan; Eman El Sayed Mohamed Journal: Int J Gen Med Date: 2022-08-18